KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Capital Expenditures (2016 - 2025)

AbbVie (ABBV) has disclosed Capital Expenditures for 14 consecutive years, with $329.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 13.06% to $329.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 24.64% increase, with the full-year FY2025 number at $1.2 billion, up 24.64% from a year prior.
  • Capital Expenditures was $329.0 million for Q4 2025 at AbbVie, down from $381.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $381.0 million in Q3 2025 to a low of $143.0 million in Q2 2022.
  • A 5-year average of $222.4 million and a median of $209.0 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 32.97% in 2021, then skyrocketed 53.01% in 2025.
  • AbbVie's Capital Expenditures stood at $187.0 million in 2021, then increased by 13.9% to $213.0 million in 2022, then fell by 3.76% to $205.0 million in 2023, then soared by 41.95% to $291.0 million in 2024, then rose by 13.06% to $329.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Capital Expenditures are $329.0 million (Q4 2025), $381.0 million (Q3 2025), and $269.0 million (Q2 2025).